HUTCHMED (China) Limited (AIM:HCM)
216.00
-6.00 (-2.70%)
Apr 8, 2026, 4:35 PM GMT
HUTCHMED (China) Revenue
In the year 2025, HUTCHMED (China) had annual revenue of $548.51M USD, down -12.96%. HUTCHMED (China) had revenue of $270.84M in the half year ending December 31, 2025, a decrease of -11.24%.
Revenue
$548.51M
Revenue Growth
-12.96%
P/S Ratio
4.68
Revenue / Employee
$305.41K
Employees
1,796
Market Cap
1.91B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 548.51M | -81.69M | -12.96% |
| Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
| Dec 31, 2019 | 204.89M | -9.22M | -4.31% |
| Dec 31, 2018 | 214.11M | -27.09M | -11.23% |
| Dec 31, 2017 | 241.20M | 25.12M | 11.63% |
| Dec 31, 2016 | 216.08M | 37.88M | 21.25% |
| Dec 31, 2015 | 178.20M | 90.87M | 104.06% |
| Dec 31, 2014 | 87.33M | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Haleon | 11.03B |
| Hikma Pharmaceuticals | 2.49B |
| ECO Animal Health Group | 85.81M |
| Animalcare Group | 81.07M |
| Allergy Therapeutics | 57.29M |
| Venture Life Group | 35.17M |
| Shield Therapeutics | 30.29M |
| Provexis | 871.27K |
HUTCHMED (China) News
- 1 hour ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 - GlobeNewsWire
- 16 days ago - HUTCHMED Initiates And Doses First Patient In Phase III Trial Of HMPL-760 For R/R DLBC Lymphoma - Nasdaq
- 17 days ago - HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China - GlobeNewsWire
- 23 days ago - HUTCHMED (China) Ltd (HCM) Shares Up 3.67% on Mar 16 - GuruFocus
- 4 weeks ago - HUTCHMED (China) Ltd (HCM) Full Year 2025 Earnings Call Highlights: Strong Global Expansion and ... - GuruFocus
- 4 weeks ago - HUTCHMED (China) Ltd (HCM) Trading 4.6% Higher on Mar 11 - GuruFocus
- 4 weeks ago - Hutchmed (HCM) Withdraws Tazverik from China Amid U.S. Market Recall - GuruFocus
- 4 weeks ago - HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China - GlobeNewsWire